News & Events

The Mac4Me project officially took off in Rotterdam, where Erasmus University Medical Center hosted its kick-off meeting.
Bringing together international partners and doctoral researchers, this Horizon Europe MSCA initiative aims to redefine metastatic cancer research through macrophage-targeted innovation.

The FDA’s move to phase out animal testing in monoclonal antibody development marks a major shift in regulatory science, highlighting New Approach Methodologies (NAMs). React4life is ready to lead this transition, advancing a future where drug development is faster and more predictive

Mac4Me, an innovative Horizon Europe Marie Skłodowska-Curie Actions Doctoral Network, brings together 14 international partners to advance research on metastatic cancer. Focusing on neuroblastoma, breast, and prostate cancer, Mac4Me uses cutting-edge organ-on-chip models and AI to identify immune targets, improving immunotherapy efficacy against metastatic disease.

React4life attended the 2025 SLAS conference in San Diego.
The event connects scientists with the latest laboratory automation and screening technologies shaping the future of research.

React4Life joins the EU-funded COMBAT project, coordinated by Karolinska Institutet, to combat the global dengue epidemic. Leveraging its advanced MIVO® organ-on-chip technology, React4Life enables precise modeling of human immune responses to dengue, accelerating the development of next-generation antiviral therapies and vaccines.

The MIVO-HTS project aims to develop a scalable organ-on-chip platform for high-throughput immuno-oncology studies. It integrates circulating human immune cells with 3D tumor models, offering predictive preclinical results while reducing animal testing.

React4Life participates in the BIO International Convention 2024 in San Diego.
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech.

MIVO® technology revolutionizes skin absorption testing by accurately replicating physiological microcirculation, improving predictions for both hydrophilic and lipophilic compounds. A recent collaboration between React4Life and Merck led to a landmark study showcasing MIVO®’s potential to bridge in vitro assays and in vivo relevance, supporting regulatory compliance and faster development of safer, more effective products.

MIVO® gut-on-chip technology provides a robust and physiologically relevant in vitro system for intestinal permeability testing, allowing simultaneous assessment of absorption, transport, and barrier function under conditions that closely mimic the human intestine.

PRESSURE, a Horizon Europe Marie Skłodowska-Curie Actions Doctoral Network, unites leading European experts to tackle therapy resistance in esophageal adenocarcinoma (EAC). By integrating omics data, patient response profiles, and advanced EAC models, PRESSURE aims to develop optimized treatments and train a new generation of researchers to revolutionize cancer therapy.